Table of Contents
ATLANTA – Revelation Pharma, a national network of 503A and 503B compounding pharmacies, announced today that it has acquired AleraCare Pharmacy—an independent compounding pharmacy within the AleraCare organization.
This acquisition is limited to AleraCare’s compounding pharmacy operations, which will be rebranded as OmniScript Compounding. OmniScript will maintain the same dedicated staff, ensuring a seamless transition of uninterrupted patient care.
“As part of our ongoing efforts to enrich our compounding pharmacy network with new partners aligned with our patient-driven mentality, this acquisition is incredibly important to us,” said Shawn Hodges, CEO of Revelation Pharma. “The pharmacy is steadfast in its unparalleled commitment to patients, as are we.”
Atlanta, GA, January 7, 2024 – Revelation Pharma, a national network of 503A and 503B compounding pharmacies, announced today that it has acquired AleraCare Pharmacy—an independent compounding pharmacy within the AleraCare organization.
This acquisition is limited to AleraCare’s compounding pharmacy operations, which will be rebranded as OmniScript Compounding. OmniScript will maintain the same dedicated staff, ensuring a seamless transition of uninterrupted patient care.
“As part of our ongoing efforts to enrich our compounding pharmacy network with new partners aligned with our patient-driven mentality, this acquisition is incredibly important to us,” said Shawn Hodges, CEO of Revelation Pharma. “The pharmacy is steadfast in its unparalleled commitment to patients, as are we.”
Learn more about Revelation Pharma’s approach to acquisitions of 503A and 503B compounding pharmacies.
Learn more about OmniScript Compounding here.
